NEW YORK (GenomeWeb News) – Agilent subsidiary Dako has entered into a "master framework agreement" with Eli Lilly to advance a companion diagnostic that gauges best responders for an undisclosed oncology treatment the drug maker is developing.

Although the initial focus of the collaboration will be to develop a test to accompany the specific drug, the framework agreement includes opportunities to expand the Rx/Dx partnership for other agents in Lilly's oncology pipeline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.